Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Erica Evans, Kevin Wilson et al.|Cancer Discovery|2018Cited by 392
American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatmentDavid C. Shonka, Gregory W. Randolph, Alan L. Ho et al.|Head & Neck|2022Cited by 110
PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung CancersAlexander Drilon, Kristoffer Staal Rohrberg, Geoffrey R. Oxnard et al.|Journal of Thoracic Oncology|2019Cited by 81
Management of treatment-related toxicities in advanced medullary thyroid cancerMarcia S. Brose, Robert I. Haddad, Keith C. Bible et al.|Cancer Treatment Reviews|2018Cited by 54